View ValuationPCC Rokita 将来の成長Future 基準チェック /46PCC Rokita利益と収益がそれぞれ年間20.4%と6.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に11% 20.6%なると予測されています。主要情報20.4%収益成長率20.65%EPS成長率Chemicals 収益成長20.2%収益成長率6.5%将来の株主資本利益率11.00%アナリストカバレッジLow最終更新日21 May 2026今後の成長に関する最新情報Major Estimate Revision • Mar 31Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from zł2.17b to zł1.94b. EPS estimate fell from zł7.37 to zł5.73 per share. Net income forecast to grow 89% next year vs 29% growth forecast for Chemicals industry in Poland. Consensus price target down from zł85.65 to zł81.80. Share price rose 4.1% to zł66.00 over the past week.Major Estimate Revision • Oct 08Consensus EPS estimates fall by 27%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from zł2.14b to zł1.95b. EPS estimate also fell from zł5.24 per share to zł3.80 per share. Net income forecast to shrink 33% next year vs 29% growth forecast for Chemicals industry in Poland . Consensus price target down from zł97.79 to zł93.32. Share price was steady at zł79.70 over the past week.Price Target Changed • Apr 27Price target increased to zł126Up from zł53.20, the current price target is provided by 1 analyst. New target price is 38% above last closing price of zł91.00. Stock is up 24% over the past year. The company posted earnings per share of zł21.02 last year.Price Target Changed • May 27Price target increased to zł75.20Up from zł53.20, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of zł73.00. Stock is up 62% over the past year.Price Target Changed • Oct 26Price target raised to zł53.69Up from zł49.20, the current price target is an average from 2 analysts. The new target price is 19% above the current share price of zł45.00. As of last close, the stock is down 9.6% over the past year.すべての更新を表示Recent updatesDeclared Dividend • Apr 23Dividend reduced to zł2.65Dividend of zł2.65 is 48% lower than last year. Ex-date: 24th April 2026 Payment date: 30th April 2026 Dividend yield will be 3.9%, which is lower than the industry average of 12%. Sustainability & Growth Dividend is covered by both earnings (69% earnings payout ratio) and cash flows (71% cash payout ratio). The dividend has increased by an average of 3.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 97% over the next 3 years, which should provide support to the dividend and adequate earnings cover.New Risk • Apr 02New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.4% net profit margin).Major Estimate Revision • Mar 31Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from zł2.17b to zł1.94b. EPS estimate fell from zł7.37 to zł5.73 per share. Net income forecast to grow 89% next year vs 29% growth forecast for Chemicals industry in Poland. Consensus price target down from zł85.65 to zł81.80. Share price rose 4.1% to zł66.00 over the past week.New Risk • Mar 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.4% Last year net profit margin: 7.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (3.4% net profit margin).お知らせ • Mar 27PCC Rokita SA, Annual General Meeting, Apr 21, 2026PCC Rokita SA, Annual General Meeting, Apr 21, 2026, at 10:00 Central European Standard Time.Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: zł1.64 (vs zł0.38 loss in 3Q 2024)Third quarter 2025 results: EPS: zł1.64 (up from zł0.38 loss in 3Q 2024). Revenue: zł414.5m (down 9.8% from 3Q 2024). Net income: zł32.6m (up zł40.0m from 3Q 2024). Profit margin: 7.9% (up from net loss in 3Q 2024). The move to profitability was driven by lower expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.お知らせ • Nov 11PCC Rokita SA to Report Q3, 2025 Results on Nov 13, 2025PCC Rokita SA announced that they will report Q3, 2025 results on Nov 13, 2025New Risk • Aug 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.1% Last year net profit margin: 17% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (6.1% net profit margin).Reported Earnings • Aug 22Second quarter 2025 earnings released: EPS: zł0.27 (vs zł1.50 in 2Q 2024)Second quarter 2025 results: EPS: zł0.27 (down from zł1.50 in 2Q 2024). Revenue: zł449.6m (down 12% from 2Q 2024). Net income: zł5.36m (down 82% from 2Q 2024). Profit margin: 1.2% (down from 5.8% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.お知らせ • Aug 20PCC Rokita SA to Report First Half, 2025 Results on Aug 20, 2025PCC Rokita SA announced that they will report first half, 2025 results on Aug 20, 2025Buy Or Sell Opportunity • Jun 30Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to zł66.10. The fair value is estimated to be zł82.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.5% over the last 3 years. Earnings per share has declined by 39%. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings are also forecast to grow by 7.0% per annum over the same time period.New Risk • May 30New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.5% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (6.5% net profit margin).Reported Earnings • May 22First quarter 2025 earnings released: EPS: zł0.14 (vs zł0.82 in 1Q 2024)First quarter 2025 results: EPS: zł0.14 (down from zł0.82 in 1Q 2024). Revenue: zł508.5m (up 3.4% from 1Q 2024). Net income: zł2.87m (down 83% from 1Q 2024). Profit margin: 0.6% (down from 3.3% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.分析記事 • Apr 29Does PCC Rokita (WSE:PCR) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Mar 31PCC Rokita SA, Annual General Meeting, Apr 24, 2025PCC Rokita SA, Annual General Meeting, Apr 24, 2025.Reported Earnings • Mar 28Full year 2024 earnings released: EPS: zł5.83 (vs zł13.49 in FY 2023)Full year 2024 results: EPS: zł5.83 (down from zł13.49 in FY 2023). Revenue: zł1.79b (down 25% from FY 2023). Net income: zł115.8m (down 57% from FY 2023). Profit margin: 6.5% (down from 11% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Reported Earnings • Nov 17Third quarter 2024 earnings released: zł0.38 loss per share (vs zł1.50 profit in 3Q 2023)Third quarter 2024 results: zł0.38 loss per share (down from zł1.50 profit in 3Q 2023). Revenue: zł459.8m (down 10% from 3Q 2023). Net loss: zł7.44m (down 125% from profit in 3Q 2023). Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Major Estimate Revision • Oct 08Consensus EPS estimates fall by 27%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from zł2.14b to zł1.95b. EPS estimate also fell from zł5.24 per share to zł3.80 per share. Net income forecast to shrink 33% next year vs 29% growth forecast for Chemicals industry in Poland . Consensus price target down from zł97.79 to zł93.32. Share price was steady at zł79.70 over the past week.Reported Earnings • Aug 22Second quarter 2024 earnings released: EPS: zł1.50 (vs zł0.76 in 2Q 2023)Second quarter 2024 results: EPS: zł1.50 (up from zł0.76 in 2Q 2023). Revenue: zł508.4m (down 9.3% from 2Q 2023). Net income: zł29.7m (up 97% from 2Q 2023). Profit margin: 5.8% (up from 2.7% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.分析記事 • May 30Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?Key Insights Using the 2 Stage Free Cash Flow to Equity, PCC Rokita fair value estimate is zł138 PCC Rokita is...Reported Earnings • May 19First quarter 2024 earnings released: EPS: zł0.82 (vs zł7.08 in 1Q 2023)First quarter 2024 results: EPS: zł0.82 (down from zł7.08 in 1Q 2023). Revenue: zł491.9m (down 37% from 1Q 2023). Net income: zł16.4m (down 88% from 1Q 2023). Profit margin: 3.3% (down from 18% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 10% per year.お知らせ • Apr 26PCC Rokita SA, Annual General Meeting, May 20, 2024PCC Rokita SA, Annual General Meeting, May 20, 2024, at 11:00 Central European Standard Time.Reported Earnings • Mar 21Full year 2023 earnings released: EPS: zł13.49 (vs zł34.00 in FY 2022)Full year 2023 results: EPS: zł13.49 (down from zł34.00 in FY 2022). Revenue: zł2.39b (down 24% from FY 2022). Net income: zł267.8m (down 60% from FY 2022). Profit margin: 11% (down from 22% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 02+ 3 more updatesPCC Rokita SA to Report Q3, 2024 Results on Nov 14, 2024PCC Rokita SA announced that they will report Q3, 2024 results on Nov 14, 2024Reported Earnings • Nov 16Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł512.3m (down 36% from 3Q 2022). Net income: zł29.8m (down 80% from 3Q 2022). Profit margin: 5.8% (down from 18% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 1.4% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Europe are expected to grow by 3.6%. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.分析記事 • Aug 24Is PCC Rokita (WSE:PCR) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Aug 23Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł560.7m (down 22% from 2Q 2022). Net income: zł15.1m (down 87% from 2Q 2022). Profit margin: 2.7% (down from 16% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 5.0% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Europe are expected to grow by 3.2%. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.Reported Earnings • May 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: zł780.0m (up 12% from 1Q 2022). Net income: zł140.5m (up 13% from 1Q 2022). Profit margin: 18% (in line with 1Q 2022). Revenue is expected to decline by 5.9% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Europe are expected to grow by 3.9%.Valuation Update With 7 Day Price Move • May 05Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to zł124, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 16x in the Chemicals industry in Poland. Total returns to shareholders of 359% over the past three years.分析記事 • Apr 29PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last YearPCC Rokita SA ( WSE:PCR ) will increase its dividend on the 10th of May to PLN21.57, which is 63% higher than last...Reported Earnings • Mar 24Full year 2022 earnings released: EPS: zł34.00 (vs zł21.02 in FY 2021)Full year 2022 results: EPS: zł34.00 (up from zł21.02 in FY 2021). Revenue: zł3.14b (up 43% from FY 2021). Net income: zł675.1m (up 62% from FY 2021). Profit margin: 22% (up from 19% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 72% per year whereas the company’s share price has increased by 68% per year.Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improves as stock rises 19%After last week's 19% share price gain to zł137, the stock trades at a trailing P/E ratio of 4.8x. Average trailing P/E is 7x in the Chemicals industry in Poland. Total returns to shareholders of 487% over the past three years.お知らせ • Feb 03+ 3 more updatesPCC Rokita SA to Report Q2, 2023 Results on Aug 22, 2023PCC Rokita SA announced that they will report Q2, 2023 results on Aug 22, 2023分析記事 • Jan 18Is PCC Rokita (WSE:PCR) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł802.5m (up 48% from 3Q 2021). Net income: zł146.5m (up 91% from 3Q 2021). Profit margin: 18% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue.Reported Earnings • Nov 13Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł802.5m (up 48% from 3Q 2021). Net income: zł146.5m (up 91% from 3Q 2021). Profit margin: 18% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Aug 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł71.50, the stock trades at a trailing P/E ratio of 2.8x. Average forward P/E is 14x in the Chemicals industry in Poland. Total returns to shareholders of 87% over the past three years.Reported Earnings • Aug 23Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł714.2m (up 28% from 2Q 2021). Net income: zł117.4m (up 30% from 2Q 2021). Profit margin: 16% (in line with 2Q 2021). Over the next year, revenue is expected to shrink by 11% compared to a 11% growth forecast for the Chemicals industry in Poland.Reported Earnings • May 20First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł697.4m (up 41% from 1Q 2021). Net income: zł123.9m (up 78% from 1Q 2021). Profit margin: 18% (up from 14% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 3.1% compared to a 17% growth forecast for the industry in Poland.Price Target Changed • Apr 27Price target increased to zł126Up from zł53.20, the current price target is provided by 1 analyst. New target price is 38% above last closing price of zł91.00. Stock is up 24% over the past year. The company posted earnings per share of zł21.02 last year.Upcoming Dividend • Apr 19Upcoming dividend of zł13.23 per shareEligible shareholders must have bought the stock before 26 April 2022. Payment date: 05 May 2022. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Polish dividend payers (7.1%). In line with average of industry peers (3.2%).分析記事 • Apr 16PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23The board of PCC Rokita SA ( WSE:PCR ) has announced that the dividend on 5th of May will be increased to zł13.23...分析記事 • Mar 19Why We Like The Returns At PCC Rokita (WSE:PCR)There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...Reported Earnings • Mar 18Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: zł21.02 (up from zł5.91 in FY 2020). Revenue: zł2.20b (up 49% from FY 2020). Net income: zł417.3m (up 256% from FY 2020). Profit margin: 19% (up from 8.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 22%. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.分析記事 • Jan 25What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?While PCC Rokita SA ( WSE:PCR ) might not be the most widely known stock at the moment, it received a lot of attention...Reported Earnings • Nov 13Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: zł541.9m (up 59% from 3Q 2020). Net income: zł76.7m (up 162% from 3Q 2020). Profit margin: 14% (up from 8.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.分析記事 • Sep 01We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł559.4m (up 70% from 2Q 2020). Net income: zł90.1m (up zł76.0m from 2Q 2020). Profit margin: 16% (up from 4.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.分析記事 • Jun 14Why PCC Rokita SA (WSE:PCR) Could Be Worth WatchingPCC Rokita SA ( WSE:PCR ), is not the largest company out there, but it led the WSE gainers with a relatively large...Price Target Changed • May 27Price target increased to zł75.20Up from zł53.20, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of zł73.00. Stock is up 62% over the past year.分析記事 • May 18Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?In this article we are going to estimate the intrinsic value of PCC Rokita SA ( WSE:PCR ) by taking the expected future...Upcoming Dividend • Apr 29Upcoming dividend of zł3.67 per shareEligible shareholders must have bought the stock before 05 May 2021. Payment date: 14 May 2021. Trailing yield: 4.7%. Lower than top quartile of Polish dividend payers (5.2%). Higher than average of industry peers (2.4%).分析記事 • Apr 13Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The BrakesIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...分析記事 • Mar 23Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They SeemPCC Rokita SA ( WSE:PCR ) announced a healthy earnings result recently, and the market rewarded it with a strong stock...Reported Earnings • Mar 19Full year 2020 earnings released: EPS zł5.91 (vs zł4.70 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: zł1.48b (down 1.1% from FY 2019). Net income: zł117.4m (up 26% from FY 2019). Profit margin: 8.0% (up from 6.3% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.分析記事 • Mar 09PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?Most readers would already be aware that PCC Rokita's (WSE:PCR) stock increased significantly by 25% over the past...Is New 90 Day High Low • Feb 26New 90-day high: zł73.60The company is up 55% from its price of zł47.60 on 27 November 2020. The Polish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period.分析記事 • Feb 19Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?Today we'll take a closer look at PCC Rokita SA ( WSE:PCR ) from a dividend investor's perspective. Owning a strong...分析記事 • Feb 04What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?While PCC Rokita SA ( WSE:PCR ) might not be the most widely known stock at the moment, it saw a significant share...Is New 90 Day High Low • Feb 02New 90-day high: zł65.80The company is up 52% from its price of zł43.40 on 04 November 2020. The Polish market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł26.46 per share.お知らせ • Feb 02+ 1 more updatePCC Rokita SA to Report Fiscal Year 2020 Results on Mar 16, 2021PCC Rokita SA announced that they will report fiscal year 2020 results on Mar 16, 2021お知らせ • Feb 01PCC Rokita SA to Report Q2, 2021 Results on Aug 18, 2021PCC Rokita SA announced that they will report Q2, 2021 results on Aug 18, 2021分析記事 • Jan 15Is PCC Rokita (WSE:PCR) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is New 90 Day High Low • Jan 07New 90-day high: zł56.80The company is up 24% from its price of zł45.70 on 09 October 2020. The Polish market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł24.99 per share.分析記事 • Dec 30Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...分析記事 • Dec 17Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three YearsPCC Rokita SA ( WSE:PCR ) shareholders should be happy to see the share price up 13% in the last month. But that cannot...Is New 90 Day High Low • Dec 04New 90-day high: zł49.10The company is up 4.0% from its price of zł47.20 on 04 September 2020. The Polish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł22.34 per share.分析記事 • Dec 03PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?PCC Rokita's (WSE:PCR) stock is up by a considerable 8.0% over the past month. However, we wonder if the company's...分析記事 • Nov 20Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?Today we'll take a closer look at PCC Rokita SA (WSE:PCR) from a dividend investor's perspective. Owning a strong...Reported Earnings • Nov 16Third quarter 2020 earnings released: EPS zł1.47The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: zł341.8m (down 12% from 3Q 2019). Net income: zł29.2m (down 22% from 3Q 2019). Profit margin: 8.6% (down from 9.6% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Oct 30New 90-day low: zł41.40The company is down 18% from its price of zł50.40 on 31 July 2020. The Polish market is down 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł22.52 per share.Price Target Changed • Oct 26Price target raised to zł53.69Up from zł49.20, the current price target is an average from 2 analysts. The new target price is 19% above the current share price of zł45.00. As of last close, the stock is down 9.6% over the past year.Is New 90 Day High Low • Sep 24New 90-day low: zł42.10The company is down 1.0% from its price of zł42.60 on 26 June 2020. The Polish market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł20.84 per share.業績と収益の成長予測WSE:PCR - アナリストの将来予測と過去の財務データ ( )PLN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20282,207155143343112/31/20272,121137132332112/31/20262,016123111306212/31/20251,80161144296N/A9/30/20251,860145181325N/A6/30/20251,905105156262N/A3/31/20251,964130199314N/A12/31/20241,947143177306N/A9/30/20241,995121188335N/A6/30/20242,048158212376N/A3/31/20242,100144111310N/A12/31/20232,388268296512N/A9/30/20232,782473511736N/A6/30/20233,072589623883N/A3/31/20233,225692691941N/A12/31/20223,143675563792N/A9/30/20222,821569392621N/A6/30/20222,560499383575N/A3/31/20222,405472399553N/A12/31/20212,203417380530N/A9/30/20212,027294328468N/A6/30/20211,827247267389N/A3/31/20211,597171200342N/A12/31/20201,476117195366N/A9/30/20201,41473149340N/A6/30/20201,46182136357N/A3/31/20201,48272123355N/A12/31/20191,4929377310N/A9/30/20191,513145N/A316N/A6/30/20191,503160N/A295N/A3/31/20191,512201N/A356N/A12/31/20181,490227N/A287N/A9/30/20181,445243N/A254N/A6/30/20181,378215N/A220N/A3/31/20181,345213N/A181N/A12/31/20171,286182N/A204N/A9/30/20171,234208N/A264N/A6/30/20171,187213N/A264N/A3/31/20171,129207N/A259N/A12/31/20161,107203N/A263N/A9/30/20161,084135N/A220N/A6/30/20161,097131N/A187N/A3/31/20161,077110N/A161N/A12/31/20151,04985N/A149N/A9/30/20151,05373N/A123N/A6/30/20151,06262N/A130N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PCRの予測収益成長率 (年間20.4% ) は 貯蓄率 ( 5.3% ) を上回っています。収益対市場: PCRの収益 ( 20.4% ) はPolish市場 ( 11.6% ) よりも速いペースで成長すると予測されています。高成長収益: PCRの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: PCRの収益 ( 6.5% ) Polish市場 ( 4.3% ) よりも速いペースで成長すると予測されています。高い収益成長: PCRの収益 ( 6.5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PCRの 自己資本利益率 は、3年後には低くなると予測されています ( 11 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/22 17:45終値2026/06/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PCC Rokita SA 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Henning EsskuchenErste Group Bank AGJakub SzkopekErste Group Bank AGAdam MilewiczPKO BP Securities
Major Estimate Revision • Mar 31Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from zł2.17b to zł1.94b. EPS estimate fell from zł7.37 to zł5.73 per share. Net income forecast to grow 89% next year vs 29% growth forecast for Chemicals industry in Poland. Consensus price target down from zł85.65 to zł81.80. Share price rose 4.1% to zł66.00 over the past week.
Major Estimate Revision • Oct 08Consensus EPS estimates fall by 27%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from zł2.14b to zł1.95b. EPS estimate also fell from zł5.24 per share to zł3.80 per share. Net income forecast to shrink 33% next year vs 29% growth forecast for Chemicals industry in Poland . Consensus price target down from zł97.79 to zł93.32. Share price was steady at zł79.70 over the past week.
Price Target Changed • Apr 27Price target increased to zł126Up from zł53.20, the current price target is provided by 1 analyst. New target price is 38% above last closing price of zł91.00. Stock is up 24% over the past year. The company posted earnings per share of zł21.02 last year.
Price Target Changed • May 27Price target increased to zł75.20Up from zł53.20, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of zł73.00. Stock is up 62% over the past year.
Price Target Changed • Oct 26Price target raised to zł53.69Up from zł49.20, the current price target is an average from 2 analysts. The new target price is 19% above the current share price of zł45.00. As of last close, the stock is down 9.6% over the past year.
Declared Dividend • Apr 23Dividend reduced to zł2.65Dividend of zł2.65 is 48% lower than last year. Ex-date: 24th April 2026 Payment date: 30th April 2026 Dividend yield will be 3.9%, which is lower than the industry average of 12%. Sustainability & Growth Dividend is covered by both earnings (69% earnings payout ratio) and cash flows (71% cash payout ratio). The dividend has increased by an average of 3.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 97% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
New Risk • Apr 02New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.4% net profit margin).
Major Estimate Revision • Mar 31Consensus revenue estimates fall by 11%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from zł2.17b to zł1.94b. EPS estimate fell from zł7.37 to zł5.73 per share. Net income forecast to grow 89% next year vs 29% growth forecast for Chemicals industry in Poland. Consensus price target down from zł85.65 to zł81.80. Share price rose 4.1% to zł66.00 over the past week.
New Risk • Mar 27New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.4% Last year net profit margin: 7.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (3.4% net profit margin).
お知らせ • Mar 27PCC Rokita SA, Annual General Meeting, Apr 21, 2026PCC Rokita SA, Annual General Meeting, Apr 21, 2026, at 10:00 Central European Standard Time.
Reported Earnings • Nov 18Third quarter 2025 earnings released: EPS: zł1.64 (vs zł0.38 loss in 3Q 2024)Third quarter 2025 results: EPS: zł1.64 (up from zł0.38 loss in 3Q 2024). Revenue: zł414.5m (down 9.8% from 3Q 2024). Net income: zł32.6m (up zł40.0m from 3Q 2024). Profit margin: 7.9% (up from net loss in 3Q 2024). The move to profitability was driven by lower expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 11PCC Rokita SA to Report Q3, 2025 Results on Nov 13, 2025PCC Rokita SA announced that they will report Q3, 2025 results on Nov 13, 2025
New Risk • Aug 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.1% Last year net profit margin: 17% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (6.1% net profit margin).
Reported Earnings • Aug 22Second quarter 2025 earnings released: EPS: zł0.27 (vs zł1.50 in 2Q 2024)Second quarter 2025 results: EPS: zł0.27 (down from zł1.50 in 2Q 2024). Revenue: zł449.6m (down 12% from 2Q 2024). Net income: zł5.36m (down 82% from 2Q 2024). Profit margin: 1.2% (down from 5.8% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 20PCC Rokita SA to Report First Half, 2025 Results on Aug 20, 2025PCC Rokita SA announced that they will report first half, 2025 results on Aug 20, 2025
Buy Or Sell Opportunity • Jun 30Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to zł66.10. The fair value is estimated to be zł82.79, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.5% over the last 3 years. Earnings per share has declined by 39%. For the next 3 years, revenue is forecast to grow by 5.4% per annum. Earnings are also forecast to grow by 7.0% per annum over the same time period.
New Risk • May 30New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.5% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (6.5% net profit margin).
Reported Earnings • May 22First quarter 2025 earnings released: EPS: zł0.14 (vs zł0.82 in 1Q 2024)First quarter 2025 results: EPS: zł0.14 (down from zł0.82 in 1Q 2024). Revenue: zł508.5m (up 3.4% from 1Q 2024). Net income: zł2.87m (down 83% from 1Q 2024). Profit margin: 0.6% (down from 3.3% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
分析記事 • Apr 29Does PCC Rokita (WSE:PCR) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Mar 31PCC Rokita SA, Annual General Meeting, Apr 24, 2025PCC Rokita SA, Annual General Meeting, Apr 24, 2025.
Reported Earnings • Mar 28Full year 2024 earnings released: EPS: zł5.83 (vs zł13.49 in FY 2023)Full year 2024 results: EPS: zł5.83 (down from zł13.49 in FY 2023). Revenue: zł1.79b (down 25% from FY 2023). Net income: zł115.8m (down 57% from FY 2023). Profit margin: 6.5% (down from 11% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Reported Earnings • Nov 17Third quarter 2024 earnings released: zł0.38 loss per share (vs zł1.50 profit in 3Q 2023)Third quarter 2024 results: zł0.38 loss per share (down from zł1.50 profit in 3Q 2023). Revenue: zł459.8m (down 10% from 3Q 2023). Net loss: zł7.44m (down 125% from profit in 3Q 2023). Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Major Estimate Revision • Oct 08Consensus EPS estimates fall by 27%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from zł2.14b to zł1.95b. EPS estimate also fell from zł5.24 per share to zł3.80 per share. Net income forecast to shrink 33% next year vs 29% growth forecast for Chemicals industry in Poland . Consensus price target down from zł97.79 to zł93.32. Share price was steady at zł79.70 over the past week.
Reported Earnings • Aug 22Second quarter 2024 earnings released: EPS: zł1.50 (vs zł0.76 in 2Q 2023)Second quarter 2024 results: EPS: zł1.50 (up from zł0.76 in 2Q 2023). Revenue: zł508.4m (down 9.3% from 2Q 2023). Net income: zł29.7m (up 97% from 2Q 2023). Profit margin: 5.8% (up from 2.7% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
分析記事 • May 30Is There An Opportunity With PCC Rokita SA's (WSE:PCR) 36% Undervaluation?Key Insights Using the 2 Stage Free Cash Flow to Equity, PCC Rokita fair value estimate is zł138 PCC Rokita is...
Reported Earnings • May 19First quarter 2024 earnings released: EPS: zł0.82 (vs zł7.08 in 1Q 2023)First quarter 2024 results: EPS: zł0.82 (down from zł7.08 in 1Q 2023). Revenue: zł491.9m (down 37% from 1Q 2023). Net income: zł16.4m (down 88% from 1Q 2023). Profit margin: 3.3% (down from 18% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 10% per year.
お知らせ • Apr 26PCC Rokita SA, Annual General Meeting, May 20, 2024PCC Rokita SA, Annual General Meeting, May 20, 2024, at 11:00 Central European Standard Time.
Reported Earnings • Mar 21Full year 2023 earnings released: EPS: zł13.49 (vs zł34.00 in FY 2022)Full year 2023 results: EPS: zł13.49 (down from zł34.00 in FY 2022). Revenue: zł2.39b (down 24% from FY 2022). Net income: zł267.8m (down 60% from FY 2022). Profit margin: 11% (down from 22% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Chemicals industry in Europe. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 02+ 3 more updatesPCC Rokita SA to Report Q3, 2024 Results on Nov 14, 2024PCC Rokita SA announced that they will report Q3, 2024 results on Nov 14, 2024
Reported Earnings • Nov 16Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł512.3m (down 36% from 3Q 2022). Net income: zł29.8m (down 80% from 3Q 2022). Profit margin: 5.8% (down from 18% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 1.4% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Europe are expected to grow by 3.6%. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
分析記事 • Aug 24Is PCC Rokita (WSE:PCR) Using Too Much Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Aug 23Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł560.7m (down 22% from 2Q 2022). Net income: zł15.1m (down 87% from 2Q 2022). Profit margin: 2.7% (down from 16% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 5.0% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Europe are expected to grow by 3.2%. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
Reported Earnings • May 21First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: zł780.0m (up 12% from 1Q 2022). Net income: zł140.5m (up 13% from 1Q 2022). Profit margin: 18% (in line with 1Q 2022). Revenue is expected to decline by 5.9% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Europe are expected to grow by 3.9%.
Valuation Update With 7 Day Price Move • May 05Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to zł124, the stock trades at a trailing P/E ratio of 3.6x. Average forward P/E is 16x in the Chemicals industry in Poland. Total returns to shareholders of 359% over the past three years.
分析記事 • Apr 29PCC Rokita's (WSE:PCR) Shareholders Will Receive A Bigger Dividend Than Last YearPCC Rokita SA ( WSE:PCR ) will increase its dividend on the 10th of May to PLN21.57, which is 63% higher than last...
Reported Earnings • Mar 24Full year 2022 earnings released: EPS: zł34.00 (vs zł21.02 in FY 2021)Full year 2022 results: EPS: zł34.00 (up from zł21.02 in FY 2021). Revenue: zł3.14b (up 43% from FY 2021). Net income: zł675.1m (up 62% from FY 2021). Profit margin: 22% (up from 19% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 72% per year whereas the company’s share price has increased by 68% per year.
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improves as stock rises 19%After last week's 19% share price gain to zł137, the stock trades at a trailing P/E ratio of 4.8x. Average trailing P/E is 7x in the Chemicals industry in Poland. Total returns to shareholders of 487% over the past three years.
お知らせ • Feb 03+ 3 more updatesPCC Rokita SA to Report Q2, 2023 Results on Aug 22, 2023PCC Rokita SA announced that they will report Q2, 2023 results on Aug 22, 2023
分析記事 • Jan 18Is PCC Rokita (WSE:PCR) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Nov 16Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł802.5m (up 48% from 3Q 2021). Net income: zł146.5m (up 91% from 3Q 2021). Profit margin: 18% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue.
Reported Earnings • Nov 13Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł802.5m (up 48% from 3Q 2021). Net income: zł146.5m (up 91% from 3Q 2021). Profit margin: 18% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Aug 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł71.50, the stock trades at a trailing P/E ratio of 2.8x. Average forward P/E is 14x in the Chemicals industry in Poland. Total returns to shareholders of 87% over the past three years.
Reported Earnings • Aug 23Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł714.2m (up 28% from 2Q 2021). Net income: zł117.4m (up 30% from 2Q 2021). Profit margin: 16% (in line with 2Q 2021). Over the next year, revenue is expected to shrink by 11% compared to a 11% growth forecast for the Chemicals industry in Poland.
Reported Earnings • May 20First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł697.4m (up 41% from 1Q 2021). Net income: zł123.9m (up 78% from 1Q 2021). Profit margin: 18% (up from 14% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 3.1% compared to a 17% growth forecast for the industry in Poland.
Price Target Changed • Apr 27Price target increased to zł126Up from zł53.20, the current price target is provided by 1 analyst. New target price is 38% above last closing price of zł91.00. Stock is up 24% over the past year. The company posted earnings per share of zł21.02 last year.
Upcoming Dividend • Apr 19Upcoming dividend of zł13.23 per shareEligible shareholders must have bought the stock before 26 April 2022. Payment date: 05 May 2022. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 3.5%. Lower than top quartile of Polish dividend payers (7.1%). In line with average of industry peers (3.2%).
分析記事 • Apr 16PCC Rokita (WSE:PCR) Is Increasing Its Dividend To zł13.23The board of PCC Rokita SA ( WSE:PCR ) has announced that the dividend on 5th of May will be increased to zł13.23...
分析記事 • Mar 19Why We Like The Returns At PCC Rokita (WSE:PCR)There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
Reported Earnings • Mar 18Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: zł21.02 (up from zł5.91 in FY 2020). Revenue: zł2.20b (up 49% from FY 2020). Net income: zł417.3m (up 256% from FY 2020). Profit margin: 19% (up from 8.0% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 22%. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
分析記事 • Jan 25What Is PCC Rokita SA's (WSE:PCR) Share Price Doing?While PCC Rokita SA ( WSE:PCR ) might not be the most widely known stock at the moment, it received a lot of attention...
Reported Earnings • Nov 13Third quarter 2021 earnings releasedThe company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: zł541.9m (up 59% from 3Q 2020). Net income: zł76.7m (up 162% from 3Q 2020). Profit margin: 14% (up from 8.6% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
分析記事 • Sep 01We Like These Underlying Return On Capital Trends At PCC Rokita (WSE:PCR)If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...
Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł559.4m (up 70% from 2Q 2020). Net income: zł90.1m (up zł76.0m from 2Q 2020). Profit margin: 16% (up from 4.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
分析記事 • Jun 14Why PCC Rokita SA (WSE:PCR) Could Be Worth WatchingPCC Rokita SA ( WSE:PCR ), is not the largest company out there, but it led the WSE gainers with a relatively large...
Price Target Changed • May 27Price target increased to zł75.20Up from zł53.20, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of zł73.00. Stock is up 62% over the past year.
分析記事 • May 18Are PCC Rokita SA (WSE:PCR) Investors Paying Above The Intrinsic Value?In this article we are going to estimate the intrinsic value of PCC Rokita SA ( WSE:PCR ) by taking the expected future...
Upcoming Dividend • Apr 29Upcoming dividend of zł3.67 per shareEligible shareholders must have bought the stock before 05 May 2021. Payment date: 14 May 2021. Trailing yield: 4.7%. Lower than top quartile of Polish dividend payers (5.2%). Higher than average of industry peers (2.4%).
分析記事 • Apr 13Returns On Capital At PCC Rokita (WSE:PCR) Have Hit The BrakesIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
分析記事 • Mar 23Why PCC Rokita's (WSE:PCR) Earnings Are Better Than They SeemPCC Rokita SA ( WSE:PCR ) announced a healthy earnings result recently, and the market rewarded it with a strong stock...
Reported Earnings • Mar 19Full year 2020 earnings released: EPS zł5.91 (vs zł4.70 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: zł1.48b (down 1.1% from FY 2019). Net income: zł117.4m (up 26% from FY 2019). Profit margin: 8.0% (up from 6.3% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
分析記事 • Mar 09PCC Rokita SA's (WSE:PCR) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?Most readers would already be aware that PCC Rokita's (WSE:PCR) stock increased significantly by 25% over the past...
Is New 90 Day High Low • Feb 26New 90-day high: zł73.60The company is up 55% from its price of zł47.60 on 27 November 2020. The Polish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period.
分析記事 • Feb 19Looking For Steady Income For Your Dividend Portfolio? Is PCC Rokita SA (WSE:PCR) A Good Fit?Today we'll take a closer look at PCC Rokita SA ( WSE:PCR ) from a dividend investor's perspective. Owning a strong...
分析記事 • Feb 04What Does PCC Rokita SA's (WSE:PCR) Share Price Indicate?While PCC Rokita SA ( WSE:PCR ) might not be the most widely known stock at the moment, it saw a significant share...
Is New 90 Day High Low • Feb 02New 90-day high: zł65.80The company is up 52% from its price of zł43.40 on 04 November 2020. The Polish market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 19% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł26.46 per share.
お知らせ • Feb 02+ 1 more updatePCC Rokita SA to Report Fiscal Year 2020 Results on Mar 16, 2021PCC Rokita SA announced that they will report fiscal year 2020 results on Mar 16, 2021
お知らせ • Feb 01PCC Rokita SA to Report Q2, 2021 Results on Aug 18, 2021PCC Rokita SA announced that they will report Q2, 2021 results on Aug 18, 2021
分析記事 • Jan 15Is PCC Rokita (WSE:PCR) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Is New 90 Day High Low • Jan 07New 90-day high: zł56.80The company is up 24% from its price of zł45.70 on 09 October 2020. The Polish market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł24.99 per share.
分析記事 • Dec 30Should We Be Excited About The Trends Of Returns At PCC Rokita (WSE:PCR)?Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
分析記事 • Dec 17Reflecting on PCC Rokita's (WSE:PCR) Share Price Returns Over The Last Three YearsPCC Rokita SA ( WSE:PCR ) shareholders should be happy to see the share price up 13% in the last month. But that cannot...
Is New 90 Day High Low • Dec 04New 90-day high: zł49.10The company is up 4.0% from its price of zł47.20 on 04 September 2020. The Polish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł22.34 per share.
分析記事 • Dec 03PCC Rokita SA's (WSE:PCR) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?PCC Rokita's (WSE:PCR) stock is up by a considerable 8.0% over the past month. However, we wonder if the company's...
分析記事 • Nov 20Are Dividend Investors Getting More Than They Bargained For With PCC Rokita SA's (WSE:PCR) Dividend?Today we'll take a closer look at PCC Rokita SA (WSE:PCR) from a dividend investor's perspective. Owning a strong...
Reported Earnings • Nov 16Third quarter 2020 earnings released: EPS zł1.47The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: zł341.8m (down 12% from 3Q 2019). Net income: zł29.2m (down 22% from 3Q 2019). Profit margin: 8.6% (down from 9.6% in 3Q 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Oct 30New 90-day low: zł41.40The company is down 18% from its price of zł50.40 on 31 July 2020. The Polish market is down 15% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł22.52 per share.
Price Target Changed • Oct 26Price target raised to zł53.69Up from zł49.20, the current price target is an average from 2 analysts. The new target price is 19% above the current share price of zł45.00. As of last close, the stock is down 9.6% over the past year.
Is New 90 Day High Low • Sep 24New 90-day low: zł42.10The company is down 1.0% from its price of zł42.60 on 26 June 2020. The Polish market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł20.84 per share.